Search - tctmd.com

Displaying 1 - 20 of 113

Sort: Relevancy | Date

News Conference News EACTS 2025

SAVR Bests TAVI for 5-Year Survival in Combined RCT, Observational Data

Yael L. Maxwell

October 10, 2025

News Daily News

Money Talk: Cardiologists Must Weigh Costs as Transcatheter Therapies Ascend

Caitlin E. Cox

August 11, 2025

News Daily News

Carbon Footprint of Surgical AVR Double the Size of TAVI’s

Yael L. Maxwell

July 15, 2025

News Daily News

Dual Approach the Best Remedy for Aortic Stenosis, Amyloidosis: Registry

Caitlin E. Cox

June 09, 2025

News Conference News EuroPCR 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

Michael O'Riordan

May 23, 2025

News Conference News EuroPCR 2025

Higher Mortality With TAVI Over Surgery in Bicuspid Aortic Stenosis

Michael O'Riordan

May 22, 2025

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

News Features

What’s in a Name: Is It Time to Choose Between TAVI and TAVR?

Yael L. Maxwell

March 27, 2025

News Conference News STS 2025

Surgery Outdoes Percutaneous Treatment for Patients With CAD, Aortic Stenosis

Yael L. Maxwell

February 05, 2025

News Conference News PCR London Valves 2024

Newest Sapien TAVI Equals Surgery in Patients With Small Aortic Annuli at 5 Years

Michael O'Riordan

November 27, 2024

News Conference News PCR London Valves 2024

Live Valve Cases Safe, With Outcomes Comparable to Trials and Practice

Michael O'Riordan

November 25, 2024

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Conference News TCT 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

Yael L. Maxwell

October 29, 2024

News Conference News TCT 2024

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

Michael O'Riordan

October 28, 2024

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

L.A. McKeown

October 28, 2024

News Conference News NY Valves 2024

Dedicated Devices for Aortic Regurgitation Supported by Meta-analysis

Todd Neale

June 13, 2024

News Conference News NY Valves 2024

TEER May Be Option for Primary MR and ‘Red Zone’ Anatomy

Todd Neale

June 11, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

News Daily News

First-Ever Performance, Quality Metrics Created for Valvular and Structural Disease

Michael O'Riordan

March 20, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

Advertisement

SAVR Bests TAVI for 5-Year Survival in Combined RCT, Observational Data

Money Talk: Cardiologists Must Weigh Costs as Transcatheter Therapies Ascend

Carbon Footprint of Surgical AVR Double the Size of TAVI’s

Dual Approach the Best Remedy for Aortic Stenosis, Amyloidosis: Registry

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

Higher Mortality With TAVI Over Surgery in Bicuspid Aortic Stenosis

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

What’s in a Name: Is It Time to Choose Between TAVI and TAVR?

Surgery Outdoes Percutaneous Treatment for Patients With CAD, Aortic Stenosis

Newest Sapien TAVI Equals Surgery in Patients With Small Aortic Annuli at 5 Years

Live Valve Cases Safe, With Outcomes Comparable to Trials and Practice

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

Dedicated Devices for Aortic Regurgitation Supported by Meta-analysis

TEER May Be Option for Primary MR and ‘Red Zone’ Anatomy

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

First-Ever Performance, Quality Metrics Created for Valvular and Structural Disease

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content